Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 4/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029127 | 0.88 | CA12 (0.67) | MEN1KMT2ACA12CA9ELANE | |
| SCHEMBL3937520 | 0.79 | HDAC1 (0.77) | CA12CA9HDAC1HDAC2 | |
| SCHEMBL20545362 | 0.78 | CA12 (0.78) | MAPTCA12CA9ELANECA2 | |
| SCHEMBL916911 | 0.78 | KMT2A (0.65) | MEN1KMT2AMAPTHDAC1SMN1; SMN2 | |
| SCHEMBL9014634 | 0.76 | RAB9A (0.76) | MEN1KMT2AMAPTCA12CA9 | |
| SCHEMBL4027170 | 0.72 | CA12 (0.57) | CA12CA9ELANECA2HDAC1 | |
| SCHEMBL16831385 | 0.71 | CA12 (0.59) | MEN1KMT2AMAPTCA12CA9 | |
| SCHEMBL6386416 | 0.71 | SMN1; SMN2 (0.58) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL13606246 | 0.71 | HDAC1 (0.73) | KMT2ACA12CA9ELANECA2 | |
| SCHEMBL3940608 | 0.69 | CA12 (0.76) | KMT2ACA12CA9ELANECA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2009-12-17 | — | — | US | disclosed |
| EP-2045246-A1 | DERIVATIVES OF BENZO[D] ISOTHIAZOLES AS HISTONE DEACETYLASE INHIBITORS | Universidad De Granada (ES) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | MEN1 4169/4885KMT2A 81/4885MAPT 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.